An anti-inflammatory property of aprotinin detected at the level of leukocyte extravasation  by Asimakopoulos, George et al.
blocking pathways of complement activation and fibri-
nolysis, as well as by inhibiting the action of proteinas-
es, such as trypsin, plasmin, and kallikrein.2 Although
used mainly for its hemostatic effects, aprotinin is also
thought to modify the inflammatory response to major
Background: Aprotinin is a serine protease inhibitor used extensively in car-
diac operations to reduce postoperative bleeding. It has also been used in tri-
als aimed at reducing the systemic inflammatory response to cardiopul-
monary bypass. It remains unclear whether the anti-inflammatory action of
aprotinin is related to its general ability to suppress leukocyte activation or
whether aprotinin can exercise effects during the leukocyte-endothelial cell
adhesion cascade.
Methods: We used intravital microscopy to study the 3 main stages of the
adhesion cascade (leukocyte rolling, firm adhesion, and extravasation) with-
in the mesenteric microcirculation of rats. This in vivo technique allows
leukocyte recruitment to be viewed directly through the transparent mesen-
tery of anesthetized animals.
Results: Aprotinin, given by continuous infusion at a clinically relevant
dose, exerted no effect on the rolling or firm adhesion responses toward local
chemoattractant N-formyl-methyl-leucyl-phenylalanine but significantly
inhibited extravasation of leukocytes (73% at 40 minutes, P = .04) into sur-
rounding tissues. In parallel in vitro experiments, aprotinin (used at 200, 800,
and 1600 kIU/mL) dose dependently inhibited neutrophil transmigration
through cultured endothelial cells in response to 3 different chemoattrac-
tants: N-formyl-methyl-leucyl-phenylalanine (P < .001 at 800 and 1600
kIU/mL), interleukin 8 (P < .05 at 200 kIU/mL and P < .001 at 800 and 1600
kIU/mL), and platelet-activating factor (P < .05 at 1600 kIU/mL).
Conclusions: Our studies have therefore revealed a novel anti-inflammatory
mechanism of aprotinin operating at the level of leukocyte extravasation.
These findings may be relevant in the prevention of systemic inflammation
after cardiopulmonary bypass through the use of protease inhibitors. 
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Aprotinin (Trasylol) is a nonspecific serine proteaseinhibitor that has been used extensively in cardiac
operations since its efficacy in reducing postoperative
bleeding was discovered in the mid-1980s.1 It possess-
es broad hemostatic properties that are mediated by
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operations through a general ability to inhibit neu-
trophil activation.3,4
The inflammatory response is characterized by the
adhesion of circulating leukocytes to microvascular
endothelium and subsequent extravasation into tissues.
Three distinct phases have been described: (1) initial
attachment and rolling of leukocytes along the vessel
wall, (2) firm adhesion, and (3) transmigration into the
extravascular tissue.5 In broad terms the first phase is
mediated by the selectin family of adhesion molecules
(E-, L-, and P-selectin), and the second is mediated by
the integrin family (leukocyte function–associated anti-
gen-1, Mac-1, and very late activation antigen-4). Least
is known about the third step, but several immunoglob-
ulin supergene family members are involved on the
endothelial side, including intracellular adhesion mole-
cule and CD31,6 whereas integrins and proteases have
been implicated on the leukocyte side.7
The systemic inflammatory response syndrome
(SIRS) is a clinical syndrome that may arise as a result
of various insults, such as major trauma, a major opera-
tion, sepsis, or cardiopulmonary bypass (CPB). SIRS is
associated with leukocyte sequestration into tissues, and
the organs affected and severity differ quite widely
among patients.8 In its extreme form SIRS can lead to
multiple organ failure that often includes adult respira-
tory distress syndrome, a condition associated with
massive leukocyte infiltration in the lung and high mor-
tality.9,10 Little direct evidence exists regarding adhesion
molecule expression involved in the sequestration of
leukocytes during SIRS. The significance of various
inflammatory mediators and leukocyte chemoattrac-
tants in acute lung injury has been investigated in ani-
mal models of CPB-related injury and also in trials
involving human subjects. Analysis of the pathophysio-
logic mechanism involved in these studies suggests that
activation of complement components and subsequent
neutrophil and monocyte activation are followed by pul-
monary endothelial injury, production of interleukin
(IL) 8 and platelet-activating factor (PAF), and migra-
tion of neutrophils and monocytes into the alveoli.11-13
We conducted this study to investigate whether apro-
tinin could exert anti-inflammatory effects at the level
of leukocyte interactions with the vessel wall. Intravital
microscopy was used to investigate leukocyte respons-
es within rat mesentery, an experimental approach that
has been instrumental in defining and resolving the 3
main phases of leukocyte recruitment during inflam-
mation in vivo.5,14 Using this technique, we have previ-
ously shown roles for endogenously generated PAF and
the adhesion molecule CD31 in leukocyte extravasation
through rat mesenteric venules.6,15 Here we report that
continuous infusion of aprotinin at a clinically relevant
dose exerted no effect on rolling or firm adhesion
events but selectively inhibited the leukocyte extrava-
sation step in response to the chemoattractant N-
formyl-methyl-leucyl-phenylalanine (fMLP). Further-
more, aprotinin dose dependently inhibited fMLP-,
IL-8–, or PAF-induced neutrophil transmigration
across human umbilical vein endothelial cell (HUVEC)
monolayers in vitro.
Methods
Materials. Aprotinin, fMLP, PAF, and endothelial cell
growth factor supplement were obtained from Sigma (Dorset,
United Kingdom). Recombinant 72 aa human IL-8 was pur-
chased from Peprotech (London, United Kingdom).
Intravital microscopy. Male Sprague-Dawley rats
(250-300 g) were purchased from Harlan-Olac (Bicester,
United Kingdom) and prepared for intravital microscopy,
as previously described.7 In brief, rats were anesthetized
intravenously with 20 mg/kg sodium pentobarbital
(Sagatal; May and Baker Ltd, Dagenham, United
Kingdom), and anesthesia was maintained intravenously
with 20 mg · kg–1 · h–1 of sodium pentobarbital.
Anesthetized animals were placed on a heated stage at
37°C, and a 1- to 2-cm midline abdominal incision was
made to expose the small intestine. A segment of the termi-
nal ileum was carefully exteriorized and placed over a trans-
parent glass window. The exposed tissue was continuously
superfused with Tyrode’s salt solution (Sigma Chemical
Co) maintained at 37°C and bubbled with 5% carbon diox-
ide in air. The whole preparation was mounted onto the
stage of a Zeiss Axioskop microscope (Carl Zeiss Ltd,
Welwyn Garden City, United Kingdom), and the mesenteric
microcirculation was viewed by means of high-magnifica-
tion water-dipping objectives. Images were monitored with
a color, chilled, video camera (C5810, Hamamatsu
Photonics United Kingdom Ltd, Enfield, United Kingdom)
mounted on the microscope and recorded by an S-VHS
videocassette recorder. Leukocyte responses were quanti-
fied in a randomly selected 100-µm segment of postcapil-
lary venule with a 25- to 40-µm diameter. Rolling cells were
defined as cells traveling visibly slower than the flowing
erythrocytes past a fixed point. At each time point the num-
ber of rolling cells was counted for 5 minutes, and the mean
value was taken. Firmly adherent cells were defined as
those that remained stationary for at least 30 seconds with-
in the 100-µm vessel segment. Leukocyte extravasation was
quantified by counting the number of cells that had emi-
grated up to 50 µm away from the vessel wall.
Baseline readings of rolling, firm adhesion, and extravasa-
tion were made before infusion with aprotinin or saline con-
trol. To design an aprotinin dose regimen in rats that did not
exceed levels achieved in clinical practice, we took into
account the fact that aprotinin was removed by renal clear-
ance at a glomerular filtration rate (~3-4 mL · kg–1 · min–1 for
a 300-g rat) that was higher compared with that of the human
patient (~1.5 mL · kg–1 · min–1 for a 70-kg human being).16
Aprotinin was given as a loading dose of 40,000 kIU/kg fol-
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lowed by an infusion of 20,000 kIU · kg–1 · h–1. The total dose
given to each rat over the course of an experiment was
approximately 60,000 kIU/kg, which compares with the total
dose given to a patient throughout a CPB operation (between
60,000-120,000 kIU/kg).17 Fifteen minutes after recording
baseline readings, fMLP was added to the Tyrode superfusant
(at a final fMLP concentration of 10–7 mol/L), and further
measurements were made over the next 60 minutes. Data are
represented as means ± SEM from 5 rats in each treatment
group. Differential white cell counts were obtained before
and after aprotinin infusion (3 rats per group) by diluting
blood 1:10 in Kimura stain18 and counting cells on a hemo-
cytometer.
Neutrophil isolation from human venous blood.
Peripheral venous blood from 5 healthy nonsmoking human
donors was anticoagulated immediately by using 2 mL of
sodium citrate 3.8% (Pharma Hameln, Hameln, Germany)
per 25 mL of blood and placed in aliquots in polypropylene
tubes. After centrifugation at 3000 rpm for 10 minutes, the
plasma was removed, and cells were mixed with 6 mL of 6%
high-molecular-weight dextran (Dextran T500; Pharmacia
Biotech, Uppsala, Sweden) and 20 mL of phosphate-buffered
saline solution. After 25 minutes to sediment red cells, the
leukocyte-rich upper layer was harvested, centrifuged at 1200
rpm for 5 minutes, resuspended in 2 mL of autologous plas-
ma, and layered onto a 2-step (74% and 50%) Percoll
(Pharmacia) gradient. After centrifugation at 1300 rpm for 10
minutes, neutrophils were collected from the top of the 74%
interface, washed twice in Roswell Park Memorial Institute
(RPMI) 1640 medium containing 2% fetal calf serum, and
counted.
Neutrophil transmigration through HUVEC monolay-
ers. HUVECs were obtained from umbilical cords by using
collagenase type II (Boehringer) digestion, as previously
described.19 HUVECs were maintained on 1% (vol/vol)
gelatin-coated (Sigma) tissue-culture flasks in growth medi-
um consisting of M199 supplemented with 20% heat-inacti-
vated (56°C for 30 minutes) fetal calf serum (HyClone
Laboratories Inc, Salt Lake City, Utah), 100 IU/mL peni-
cillin, 100 µg/mL streptomycin, 2 × 10–6 mol/L L-glutamine,
10 U/mL heparin, and 30 µg/mL endothelial cell growth fac-
tor (Sigma). HUVEC monolayers were established 1 day
before transmigration experiments on cell culture inserts
(3.0-µm pore size filters, Falcon; Becton-Dickinson, Franklin
Lakes, NJ) coated with 50 µg/mL fibronectin. After excess
fibronectin had been rinsed off, inserts were placed into 24-
well plates (Nunclon; Nalge Nunc International, Denmark),
and 1 × 105 HUVECs were added to each insert. After
overnight incubation, endothelial cells were preincubated for
60 minutes with aprotinin at 3 doses (200, 800, or 1600
kIU/mL). Filters were washed with RPMI medium, and sub-
sequently, RPMI containing fMLP (10–9 mol/L), IL-8 (10–9
mol/L), or PAF (10–6 mol/L) was added to the lower chamber.
Neutrophils were preincubated with aprotinin or medium for
15 minutes and added at 1 × 106 to the upper surface of filter
inserts. Neutrophil transmigration was measured after 60
minutes by removing filters and counting cells that had
migrated into the lower chamber. So that the independent
effects of aprotinin on endothelial cells or neutrophils could
be studied, transmigration experiments were also performed
by preincubating HUVECs only or neutrophils only with
aprotinin (1600 kIU/mL) before chemotactic responses to
fMLP or IL-8.
Myeloperoxidase assay. Peripheral venous blood collect-
ed as described above was preincubated with aprotinin at 3
doses (200, 800, and 1600 kIU/mL) for 15 minutes at room
temperature on a rotating wheel, followed by a further 60-
minute incubation in the presence of fMLP (10–7 mol/L).
Plasma was obtained from whole blood at the end of the
experimental treatment period by means of centrifugation at
3000 rpm for 10 minutes and stored at –70°C until analysis.
The enzyme-linked immunossay for myeloperoxidase was
performed with 100 µL of human plasma in a 96-well
microplate format according to the manufacturer’s instruc-
tions (OXIS International Inc, Portland, Ore). Plasma sam-
ples and myeloperoxidase standards were assayed in dupli-
cate, and concentrations were calculated from a standard
curve. Results are expressed as means ± SEM from 5
donors.
Statistical analysis. Data from intravital studies were ana-
lyzed by means of the Mann-Whitney U test for the compar-
ison of nonparametric data (GraphPad Prism Software, Inc,
San Diego, Calif). Neutrophil transmigration and myeloper-
oxidase enzyme-linked immunosorbent assay data were ana-
lyzed by a 1-way analysis of variance with a Newman-Keuls
post-test (GraphPad Prism).
Results
Aprotinin inhibits leukocyte extravasation in
vivo.  In exteriorized rat mesenteric tissues, there was
a basal level of leukocyte rolling ranging between 5
and 33 cells/min, a low level of firmly adherent leuko-
cytes within venules, and a small number of leuko-
cytes in the extravascular tissue (Figs 1 and 2). After
the topical application of the chemoattractant fMLP
(10–7 mol/L), although there was no change in the
rolling flux response, leukocyte adhesion and extrava-
sation were significantly increased in a time-depen-
dent manner (Fig 1).
Aprotinin was infused into rats by using a protocol
equivalent to the high-dose regimen used in CPB,
which aims to achieve a constant concentration of 200
kIU/mL in the circulation throughout the duration of
the procedure.17 Each experiment was approximately
90 minutes in duration, consisting of 15 minutes to
exteriorize the mesentery, 15 minutes to pretreat with
aprotinin or saline control, and 60 minutes to observe
leukocyte trafficking in response to fMLP. In fMLP-
treated venules aprotinin exerted no significant effect
on leukocyte rolling (Fig 1, A) or firm adhesion (Fig 1,
B) but significantly inhibited extravasation at 40 min-
utes (P < .05) and 60 minutes (P < .05; Fig 1, C). Fig 2
depicts a representative venule from each treatment
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group, which demonstrates that emigration of leuko-
cytes up to 50 µm from the vessel wall was attenuated
by aprotinin (Fig 2, F) compared with the control group
(Fig 2, E). This effect was not caused by possible alter-
ations in circulating white cell counts because there
was no significant difference between the aprotinin and
saline treatment groups for these variables (Table I).
Furthermore, it is highly unlikely that the observed
effects were caused by alterations in microhemody-
namic variables because aprotinin had no effect on
leukocyte rolling, a response that is highly susceptible
to changes in hemodynamic factors.20
Aprotinin inhibits neutrophil extravasation in
vitro.  Because protease inhibitors have been previous-
ly shown to inhibit leukocyte transmigration through
cultured endothelial cells,21 in parallel with the in vivo
investigations, we investigated the effect of aprotinin
on leukocyte extravasation in vitro. In these experi-
ments purified human neutrophils were added to con-
fluent lawns of HUVECs grown on transwell filter
inserts (3-µm pore size), and endothelial transmigra-
tion was measured in response to chemoattractant
added to the lower chamber. A portion (7.3%) of cells
added to the upper chamber spontaneously transmi-
grated into the lower chamber, and this was increased
to 25.7% by the addition of chemoattractant fMLP
(10–9 mol/L) to the lower chamber (Fig 3, A). Aprotinin
significantly inhibited the extravasation response to the
level of background at 800 kIU/mL (P < .001) and
below levels of background at 1600 kIU/mL (P < .001).
IL-8 and PAF are chemoattractants that are thought to
be involved in the recruitment of neutrophils in the
alveolar space in acute lung injury.11,13 IL-8 (10–9
mol/L) was the most potent chemotactic stimulus used
in these studies, promoting 46.1% of cells to transmi-
grate, but this response was also significantly attenuat-
ed by aprotinin at 200 kIU/mL (P < .05), 800 kIU/mL
(P < .001), and 1600 kIU/mL (P = .001). Similarly,
transmigration in response to PAF (10–6 mol/L) was
significantly inhibited to the level of background by
aprotinin at 1600 kIU/mL (P < .05; Fig 3, C). Thus,
aprotinin dose dependently and significantly inhibited
in vitro transmigration of neutrophils in response to the
chemoattractants fMLP, IL-8, and PAF.
To address which cell type was targeted by aprotinin
in the in vitro transmigration assay, we compared the
effect of preincubating neutrophils or HUVECs alone
with the effect of treating both cells in combination, as
in the preceding experiments. This analysis showed
that preincubation of either neutrophils (15 minutes) or
HUVECs (60 minutes) alone incompletely inhibited
chemotactic responses to fMLP but that combined
treatment of both cell types reduced transmigration to
background levels (Fig 4, A). Similar additive respons-
es were observed by using IL-8 as a chemotactic stim-
ulus (Fig 4, B). Thus, we have demonstrated that the
inhibition of transendothelial migration by aprotinin is
likely to involve a complex mechanism of action,
involving potential target molecules on both the trans-
migrating leukocyte and endothelial cell.
Effect of aprotinin on neutrophil myeloperoxidase
secretion. Neutrophil migration into the subendothelial
364 Asimakopoulos et al The Journal of Thoracic and
Cardiovascular Surgery
August 2000
Fig 1. Aprotinin inhibits leukocyte extravasation but not
leukocyte rolling or firm adhesion within rat mesenteric
venules. Leukocyte endothelial cell responses were quanti-
fied during a 60-minute time course after fMLP application
(10–7 mol/L) in randomly selected 100-µm mesenteric vessel
segments from each animal. Aprotinin did not affect leuko-
cyte rolling (A) or firm adhesion (B) but significantly attenu-
ated transmigration through the vessel wall at 40 and 60 min-
utes after topical application of fMLP (C). Results are
expressed as means ± SEM (n = 5 animals). *P < .05.
A
B
C
space, recruitment into alveoli, and activation with
release of granular contents are regarded as decisive steps
in acute lung injury.22 We wished therefore to examine
whether aprotinin could inhibit myeloperoxidase secre-
tion from neutrophils. This was studied by measuring the
release of myeloperoxidase from human neutrophils in
whole blood in response to fMLP. Aprotinin dose depen-
dently inhibited myeloperoxidase secretion, which
diminished progressively to media levels at 800 kIU/mL
(P < .05; Fig 5). We have therefore demonstrated that
aprotinin, in addition to inhibiting extravasation, can also
inhibit secretion of myeloperoxidase from neutrophils. In
a clinical setting these properties of aprotinin may com-
bine to limit lung injury after CPB.
Discussion
We have shown that aprotinin can inhibit leukocyte
extravasation at a clinically relevant dose both in vivo and
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Table I. Effect of aprotinin infusion on peripheral blood counts
Before infusion After infusion
Total Mononuclear cells Granulocytes Total Mononuclear cells Granulocytes
Saline
Experiment 1 4.33 × 106 3.02 × 106 1.31 × 106 2.64 × 106 1.64 × 106 1.00 × 106
Experiment 2 5.92 × 106 4.60 × 106 1.31 × 106 3.26 × 106 2.53 × 106 7.30 × 105
Experiment 3 5.54 × 106 3.92 × 106 1.62 × 106 3.14 × 106 2.02 × 106 1.12 × 106
Aprotinin*
Experiment 1 4.77 × 106 3.76 × 106 1.01 × 106 2.70 × 106 1.46 × 106 1.24 × 106
Experiment 2 5.50 × 106 4.42 × 106 1.08 × 106 2.88 × 106 2.28 × 106 6.00 × 105
Experiment 3 6.46 × 106 5.06 × 106 1.40 × 106 2.21 × 106 1.20 × 106 1.01 × 106
Peripheral venous blood was collected from rats (n = 3) before and after saline or aprotinin infusion. Peripheral blood was differentially stained by using Kimura’s
stain,28 and total white cells, mononuclear cells, and granulocytes were counted on a hemocytometer. Results are expressed as cells per milliliter.
*None of the aprotinin treatment groups differed significantly from the saline control groups.
Fig 2. Effect of aprotinin on leukocyte endothelial cell responses viewed by intravital microscopy.
Photomicrographs of representative segments of postcapillary venule in rat mesentery are shown, as viewed by
intravital microscopy. Both saline control (A) and aprotinin-treated animals (B) exhibited a basal leukocyte rolling
flux before application of fMLP. Twenty minutes after fMLP, firm adhesion was evident in both control (C) and
aprotinin-treated animals (D). Forty minutes after fMLP, leukocytes that had transmigrated were visible around the
postcapillary venule (arrows) in control (E) but not aprotinin-treated animals (F) (bar = 50 µm).
in vitro. This was demonstrated by results of intravital
microscopy studies in rat mesentery in response to the
chemoattractant fMLP, as well as in transmigration
assays through HUVECs in response to the neutrophil
chemoattractants fMLP, IL-8, and PAF. Our experiments
comprise the first direct demonstration that a step in the
leukocyte adhesion cascade can be inhibited by aprotinin
and may explain previous observations of reduced leuko-
cyte recruitment in the presence of protease inhibitors
within the lung after CPB or in experimental models of
pneumonitis in sheep.23,24
The strength of the in vivo work lies in the ability of
intravital microscopy to provide a direct measure of sep-
arate stages of the leukocyte-endothelial cell adhesion
cascade. With this technique, we were able to demon-
strate that intravenous aprotinin at a dose equivalent to
that used in cardiac operations (see the “Methods” sec-
tion) could exert a specific inhibitory effect on leuko-
cyte extravasation induced by fMLP without concomi-
tant effects on leukocyte rolling or firm adhesion.
Results in the animal model, which used fMLP as an
acute topical chemoattractant, were supported by in
vitro transmigration experiments and extended to two
further chemoattractants, IL-8 and PAF, which are rele-
vant to lung injury.11,13 Chemotactic responses to all 3
stimuli were approximately 20% to 30% diminished in
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Fig 3. Aprotinin inhibits neutrophil transmigration across HUVECs in response to fMLP, IL-8, and PAF. Freshly
isolated neutrophils from human venous blood were allowed to transmigrate in the presence of the indicated doses
of aprotinin for 60 minutes through cultured endothelial cells on filters (3-µm pore size) in response to the follow-
ing chemoattractants in the lower chamber: fMLP (10–9 mol/L, A), IL-8 (10–9 mol/L, B), and PAF (10–6 mol/L, C).
Neutrophils and HUVECs were pretreated with aprotinin for 15 and 60 minutes, respectively, before the addition
of chemoattractant in the lower chamber. Results are expressed as mean percentage of cells transmigrated ± SEM
from 5 experiments by using separate HUVEC isolates and peripheral blood donors. *P < .05; **P < .001 from
chemoattractant without aprotinin.
A
B C
the in vitro studies at a clinically relevant 200 kIU/mL
dose of aprotinin, whereas higher doses virtually abol-
ished transmigration. The in vitro model also demon-
strated that aprotinin could target either neutrophils or
endothelial cells independently. Both experimental
models are representative of a short-term response to
local chemoattractant. We therefore consider it unlikely
that aprotinin exerted its effects by suppressing
endothelial cell activation, although it remains possible
that chemoattractants may have primed endothelial cell
function, as has been previously reported by the careful
analysis of cell shape change by electron microscopy in
the in vivo responses to fMLP.25 We are currently
extending the study of aprotinin to longer term models
of leukocyte extravasation that involve the explicit prior
activation of endothelial cells.
In a physiologic context the possible mechanism of
action of aprotinin falls into two main categories: (1)
direct effects on proteases involved in the transmigra-
tion process or (2) indirect effects brought about
through diminished neutrophil activation. With respect
to the first possibility, the elastase and cathepsin fami-
lies of serine proteases have been implicated in both the
extravasation and tissue migration processes and may
therefore represent direct targets for aprotinin.7,21
Another family of proteases involved in cell migration
are the metalloproteinases.7 Metalloproteinase-2
(gelatinase A), for example, has been found at the lead-
ing edge of migrating cells in the form of a covalent
complex bound to integrin α
v
β3.26 A possible indirect
effect of aprotinin on metalloproteinases may occur as
a result of its well-documented inhibition of plasmin.
Recent animal studies involving mice deficient in plas-
minogen and components of the plasminogen-activat-
ing system have shown that plasmin may play a critical
role in the proteolytic activation of latent metallopro-
teinase proenzymes, a necessary event during the
migration of monocytes across the elastic lamina.27,28
The second major possible mechanism of action, that
aprotinin may block extravasation as a consequence of
diminished leukocyte activation, is also plausible. In
this respect aprotinin has been previously shown to
block the activation-dependent secretion of elastase
from neutrophils and cell-surface expression of Mac-1,
events that could both play a role in leukocyte extrava-
sation.3,4 In the present study we have also shown that
aprotinin can block secretion of the neutrophil granule
component myeloperoxidase, and in the clinical setting
this effect may act synergistically with diminished
extravasation to limit leukocyte damage to inflamed
organs. Candidate-signaling molecules capable of
transducing proteolytic signals into the cell include the
protease-activated receptor family.29 Although these
are poorly studied on leukocytes, we have observed
that protease-activated receptor-1–dependent responses
in platelets are blocked by aprotinin (Poullis M,
Manning R, Laffan M, Haskard DO, Taylor KM,
Landis RC; see page 370), therefore supporting a pos-
sible role for protease-activated receptors as targets for
the anti-inflammatory action of aprotinin. Taken
together, the above lines of evidence suggest that the
molecular targets of aprotinin in the extravasation
process are likely to be complex, consisting of multiple
targets both in the soluble phase and associated with
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Fig 4. Aprotinin can target neutrophils or endothelial cells in isolation. Chemotactic responses to fMLP (A) and
IL-8 (B) were carried out as described in the legend to Fig 3, pretreating either neutrophils (15 minutes) or
HUVECs (60 minutes) alone or in combination with aprotinin at a dose of 1600 kIU/mL. Results shown are from
representative experiments expressed as mean percentage of cells transmigrated ± SD. All assays were performed
in duplicate.
A B
the cell surface of endothelial cells, migrating leuko-
cytes, or both.
The question arises as to whether other proteases
with greater selectivity than aprotinin may represent
an alternative treatment strategy to combat the sys-
temic inflammatory response after a major operation.
One of the advantages of using aprotinin in trials
aimed at reducing systemic inflammation is that
unlike other agents, aprotinin is already in clinical
use (Trasylol) and has sufficiently low toxicity when
administered in the approved dose. Another advan-
tage is that its broad spectrum of action may provide
anti-inflammatory protection in addition to proven
hemostatic benefits. Activation of complement,
secretion of inflammatory cytokines, and neutrophil
activation are all important steps in the inflammatory
cascade that are targeted by aprotinin. The use of sen-
sitive markers of leukocyte activation suggest that a
majority of patients may experience at least a mea-
surable degree of neutrophil activation during
CPB,4,30 although certain groups of patients may be
primed to react more severely on the basis of emer-
gency operation, poor cardiac output, or sepsis.8,10,30
Our findings may be of particular relevance to such
patient groups at risk of SIRS because the leukocyte
extravasation step might be more effectively treated
through higher doses of aprotinin or, in due course,
other classes of protease inhibitors with greater spe-
cific activity or longer circulating half-life than apro-
tinin.
In conclusion, our study has revealed that leukocyte
extravasation, a necessary step in the inflammatory
cascade, is inhibited by aprotinin. Because this effect
was achieved with a clinically relevant dose of apro-
tinin, it is likely that aprotinin exerts an anti-inflamma-
tory effect by reducing leukocyte extravasation when
used in patients undergoing CPB. Additional patient
benefits may be achieved in the future through the
identification of protease inhibitors with more specific
anti-inflammatory activities.
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